UnknownPhase 2

The Use of Steri3X for Prevention of Post-operative Wound Infections in Cesarean Sections

United States1,000 participantsStarted 2023-02-07

Plain-language summary

Postpartum infection if a major cause of maternal morbidity and mortality and surgical site infections are some of the common complications following cesarean section. This study aims to determine the effect of Steri3X on the incidence of cesarean section SSI at Regional One Hospital.

Who can participate

Age range16 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 16 years old or older * C-section patients only (primary, repeat, or stat) * Diabetes, obesity ok to include (but not required) * Patients receiving PCN for GBS prophylaxis ok to include (but not required) * Application of Steri3X immediately post-op Exclusion Criteria: * Chorioamnionitis or other existing infection excluded (Single maternal fever \>39 C, 2 maternal fevers \> 38, or clinical risk factors for chorioamnionitis) * Patients receiving antibiotic treatment for existing or prior infection other than PCN for GBS prophylaxis * Patients receiving Prevena or other wound vac * Rupture of membranes \>24 hours

What they're measuring

Surgical Site Infection

Timeframe: 8 weeks

Trial details

NCT IDNCT05392400

SponsorUniversity of Tennessee

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-02-07

Contact for this trial

Bethany Erickson, MD

7012268304 bericks5@uthsc.edu

View on ClinicalTrials.gov More Surgical Site Infection trials